News and Events
UPDATE on July 23, 2019:
PrimeVax Receives FDA's OK to Use Dengue Virus for Cancer Treatement
UPDATE on June 27, 2019:
PrimeVax's third clinical trial is now live on clinicaltrials.gov.
--- https://clinicaltrials.gov/ct2/show/NCT03990493
UPDATE on June 27, 2019:
PrimeVax's second clinical trial is now live on clinicaltrials.gov.
--- https://clinicaltrials.gov/ct2/show/NCT03989895
UPDATE on June 6, 2019:
PrimeVax receives IND Permission from FDA for all 3 arms of the our clinical trials, including the dengue virus arms.
--- Globe Newswire press release
UPDATE on January 22, 2019:
PrimeVax signs a worldwide exclusive license with the US Army for the use of the Army's dengue virus strain in cancer patients.
UPDATE on January 17, 2019:
PrimeVax's first clinical trial is now live on clinicaltrials.gov.
--- https://clinicaltrials.gov/ct2/show/NCT03803397
UPDATE on January 07, 2019:
PrimeVax has recently been granted the Investigational New Drug (IND) permission to run our Phase I clinical trial. We are currently mobilizing our first trial site.
UPDATE on May 19, 2017:
PrimeVax will be speaking at the World Immunotherapy Congress in San Diego on May 23:
---- Conference Agenda
UPDATE on February 21, 2017:
PrimeVax will be speaking at the Biocom Global Life Sciences Partnering Conference in San Diego on March 2:
---- PR Newswire press release
In 2020, PrimeVax will make our way to the clinic: we intend to treat metastatic melanoma patients in a phase 1 human clinical trials at multiple trial sites.
From 2017 - 2018, PrimeVax enabled our IND.
From 2015 - 2016, PrimeVax conducted various pre-clinical experiments demonstrating mechanism of action and the potential to be translated in human clinical trials.
For the latest details on our company's progress, please follow us on Twitter at @primevax.